Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study.

Journal of Blood Medicine
Anna RagoVincenzo Russo

Abstract

The aim of the present study was to assess the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients undergoing electrical cardioversion (EC). A propensity score-matched analysis was performed in order to identify two homogeneous groups including AF patients on NOACs and VKAs treatment scheduled for EC. The primary safety endpoint was major bleeding. The composite of stroke, transient ischemic attack (TIA) and systemic embolism (SE) was the primary effectiveness endpoint. The discontinuation rate of anticoagulant therapy was assessed. A total of 495 AF patients on NOACs therapy and scheduled for EC were compared to 495 VKAs recipients. No statistically significant differences in the incidence of both major bleeding (1.01% versus 1.4%; P= 0.5) and thromboembolic events (0.6% versus 0.8%; P= 0.7) were observed during a mean follow-up of 15 ± 3 months. The discontinuation rate of NOACs was significantly lower compared to VKAs (1.6% versus 3.6%, P=0.04). We showed a safe and effective clinical profile of NOACs among AF patients scheduled for electrical cardioversion in real-life setting. Patients on NOACs therapy showed a lower disco...Continue Reading

References

Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Mar 19, 2013·Journal of the American College of Cardiology·Jonathan P PicciniUNKNOWN ROCKET AF Steering Committee & Investigators
Jul 16, 2013·Journal of the American College of Cardiology·K E Juhani AiraksinenJuha E K Hartikainen
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Sep 4, 2014·European Heart Journal·Riccardo CappatoStefan H Hohnloser
Feb 14, 2015·Medical Devices : Evidence and Research·Riccardo ProiettiVidal Essebag
Mar 31, 2016·Clinical Cardiology·Anna PlittUNKNOWN ENGAGE AF-TIMI 48 Investigators
Oct 7, 2017·Journal of Cardiovascular Medicine·Vincenzo RussoGerardo Nigro
Nov 11, 2017·International Journal of Cardiology·Emanuele BertagliaGiuseppe Stabile
Feb 7, 2018·Journal of Thrombosis and Thrombolysis·Natale Daniele BrunettiMatteo Di Biase
Aug 18, 2018·Seminars in Thrombosis and Hemostasis·Vincenzo RussoGerardo Nigro
Oct 13, 2018·Journal of the American College of Cardiology·Dipak KotechaPaulus Kirchhof
Dec 13, 2018·Journal of Cardiovascular Medicine·Paolo VerdecchiaArianna Iorio
Mar 12, 2019·Journal of Cardiovascular Pharmacology·Vincenzo RussoGerardo Nigro

❮ Previous
Next ❯

Software Mentioned

ENSURE
VeRT
EMANATE
RStudio

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.